The agreement positions K2 Therapeutics, a firm established by investment group MPM BioImpact, to advance ATG-106, a CDH6 x CD3 bispecific candidate designed to treat solid tumors. By utilizing Antengene’s proprietary AnTenGager platform, the drug aims to overcome safety challenges common in first-generation TCEs through steric hindrance-based masking and fast on/off CD3 binding kinetics. This design is intended to minimize cytokine release syndrome while maintaining anti-tumor efficacy.
In section Releases
Antengene Licenses Solid Tumor TCE Program to K2 Therapeutics
Antengene has entered into an exclusive global licensing agreement with K2 Therapeutics for the preclinical bispecific T cell engager ATG-106. The deal, which grants K2 rights outside Greater China, also includes an option for a second undisclosed TCE program, potentially netting Antengene up to USD 1.9 billion across both assets.
Under the terms of the deal, Antengene will receive approximately USD 20 million in upfront and near-term payments for ATG-106, with potential milestone payouts reaching USD 960.5 million plus tiered royalties. A similar financial structure applies to the second, undisclosed program should K2 exercise its option. This transaction marks the second major partnership for the AnTenGager platform, following a global deal with UCB for ATG-201 announced in March 2026. K2 Therapeutics intends to leverage its hub-and-spoke model to accelerate these programs toward clinical development.
Comments (0)
No comments yet. Be the first!